GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)
GSK plc is a pharma worthy of a Buy rating, based on past performance and future prospects. In 2025, the company grew revenues by 7% and core EPS by 12%. GSK seems to have successfully pivoted into a "pure-play" Pharma having ditched its consumer healthcare division - despite some looming patent expiries, its pipeline looks promising enough to cope.
Citi lifts GSK target price but keeps neutral stance after rally
Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sharp rally driven by improving investor sentiment. The broker said full-year 2025 earnings per share were 2% ahead of consensus, with constant exchange rate guidance for 2026 broadly in line with expectations.
GSK Gets EU Approval for Expanded Use of Nucala in COPD
GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.
ShoreCap says GSK has cracked it and the £40bn prize is now in sight
Yesterday's results looked solid. Today Shore Capital goes further, arguing GSK has effectively delivered its medium-term plan a year early and that a £40 billion revenue ambition for 2031 is now credible, with 2,500p “justifiable” on the shares.
GSK plc (GSK) Q4 2025 Earnings Call Transcript
GSK plc (GSK) Q4 2025 Earnings Call Transcript
GSK beat the numbers, but the real story was the guidance
A clean fourth-quarter beat pushed GSK ahead of its own medium-term targets. Yet management chose to set a deliberately modest bar for 2026, leaving investors to decide whether this is prudence or opportunity.
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook
GSK's Q4 earnings and sales top estimates as strong specialty medicine demand fuels growth and drives shares higher on an upbeat 2026 outlook.
GSK (GSK) Surpasses Q4 Earnings and Revenue Estimates
GSK (GSK) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.59 per share a year ago.
GSK delivers solid 2025 results, reaffirms growth outlook for 2026
Specialty Medicines drive strong sales as company maintains guidance and raises dividend GSK PLC (LSE:GSK, NYSE:GSK) reported a 7% rise in sales for 2025 to £32.7 billion, led by strong performance in Specialty Medicines, which grew 17% to £13.5 billion. Sales in HIV, Oncology and Respiratory, Immunology & Inflammation divisions all posted double-digit gains.
GSK's Specialty Medicines Drive Solid Results
The pharma company posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for 2025, with sales of £32.67 billion.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
